← back to search

Markus Schick

AstraZeneca (Germany) · DE
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Ubiquitin and proteasome pathways, Cancer Immunotherapy and Biomarkers, Radiomics and Machine Learning in Medical Imaging, and AI in cancer detection.
h-index
17
citations
924
works
55
NIH funding
primary concept
email

Recent publications

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Molecular Cancer 2024cited by 38position: middledoi
Activation of gp130 signaling in T cells drives T <sub>H</sub> 17-mediated multi-organ autoimmunity
Science Signaling 2024cited by 8position: middledoi
Actionable loss of SLF2 drives B‐cell lymphomagenesis and impairs the DNA damage response
EMBO Molecular Medicine 2023cited by 4position: lastdoi
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Journal of Clinical Investigation 2022cited by 83position: middledoi
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Proceedings of the National Academy of Sciences 2022cited by 38position: middledoi
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
Nature Communications 2022cited by 34position: firstdoi
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
Blood Advances 2022cited by 31position: middledoi
Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
Haematologica 2022cited by 9position: middledoi
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness
Leukemia 2021cited by 15position: middledoi
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
Blood Advances 2021cited by 9position: middledoi
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 3position: middledoi
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Gut 2020cited by 100position: middledoi
The SUMO pathway in pancreatic cancer: insights and inhibition
British Journal of Cancer 2020cited by 38position: middledoi
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
Cancers 2020cited by 32position: middledoi
Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System
Biomedicines 2020cited by 5position: middledoi
The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics
Cell Reports 2019cited by 72position: middledoi
PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
Nature Communications 2019cited by 49position: middledoi
Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention
Cancer Cell 2019cited by 47position: middledoi
Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma
JCI Insight 2019cited by 24position: middledoi
Characterization of retroviral vector derived DNA-isoforms by PCR and sequencing
Journal of Consumer Protection and Food Safety 2019cited by 0position: middledoi
REGGAE: a novel approach for the identification of key transcriptional regulators
Bioinformatics 2018cited by 9position: middledoi
Pathogenesis and therapeutic targeting of aberrant <scp>MYC</scp> expression in haematological cancers
British Journal of Haematology 2017cited by 45position: firstdoi
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Haematologica 2016cited by 66position: middledoi
The Protein Targeting Factor Get3 Functions as ATP-Independent Chaperone under Oxidative Stress Conditions
Molecular Cell 2014cited by 87position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ulrich Keller · SLK-Kliniken Heilbronn16 papers (2016–2023)Matthias Wirth · TUM Klinikum8 papers (2020–2023)Stefan Habringer · University of Applied Sciences Upper Austria5 papers (2016–2022)Stefan Müller · Goethe University Frankfurt4 papers (2019–2023)Katja Steiger · Technical University of Munich4 papers (2016–2023)Stefanos A. Bamopoulos · Max Delbrück Center4 papers (2020–2022)Konstandina Isaakidis · Max Delbrück Center3 papers (2021–2023)Florian Bassermann · TUM Klinikum3 papers (2021–2023)Uta M. Demel · Max Delbrück Center3 papers (2022–2023)Roland Rad · Molecular Oncology (United States)3 papers (2019–2023)Günter Schneider · University of Göttingen3 papers (2020–2022)Chuanbing Zang · Max Delbrück Center3 papers (2021–2023)Hazal Köse · Humboldt-Universität zu Berlin3 papers (2021–2022)Nikita Singh · Pushpawati Singhania Research Institute3 papers (2020–2022)Josefina Doffo · Humboldt-Universität zu Berlin2 papers (2021–2022)Jan Krönke · Universität Ulm2 papers (2020–2022)Jan Keiten‐Schmitz · Goethe University Frankfurt2 papers (2019–2023)Leticia Quintanilla‐Martínez · University Children's Hospital Tübingen2 papers (2019–2021)H. Carlo Maurer · Columbia University Irving Medical Center2 papers (2019–2021)Felix Orben · Technical University of Munich2 papers (2021–2022)